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a b s t r a c t
The new revised ESC Guidelines focussing on clinical management of pulmonary embolism
has been published in 2014 October issue of EHJ, and it represents current knowledge in
respect of optimal diagnosis, assessment and treatment of patients with PE. Czech Society of
Cardiology prepared shortened version of the new guidelines, which is published in this
issue of Cor et Vasa. In our manuscript we focussed on the most important differences
between these two guidelines: Recently identiﬁed predisposing factors for venous throm-
boembolism, simpliﬁcation of clinical prediction rules, age-adjusted D-dimer cut-offs, sub-
segmental pulmonary embolism, incidental, clinically unsuspected pulmonary embolism,
advanced risk stratiﬁcation of intermediate-risk pulmonary embolism, initiation of treat-
ment with vitamin K antagonists, treatment and secondary prophylaxis of venous throm-
boembolism with the new direct oral anticoagulants, efﬁcacy and safety of reperfusion
treatment for patients at intermediate risk, early discharge and home (outpatient) treatment
of pulmonary embolism, current diagnosis and treatment of chronic thromboembolic
pulmonary hypertension and ﬁnally, formal recommendations for the management of
pulmonary embolism in pregnancy and of pulmonary embolism in patients with cancer.
# 2015 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights
reserved.
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Introduction
Venous thromboembolism (VTE) is the third most frequent
cardiovascular disease with an overall annual incidence of
100–200 per 100 000 inhabitants. PE is associated with
signiﬁcant morbidity and mortality. From all the patients
suffering PE as many as 15% will die within the ﬁrst month and
of those who do survive, 30% will develop recurrent PE over the
following 10 years. Of those who died, only 7% were correctly
diagnosed during life.
The new revised ESC Guidelines focussing on clinical
management of pulmonary embolism has been published in
(6) Advanced risk stratiﬁcation of intermediate-risk pulmo-
nary embolism
(7) Initiation of treatment with vitamin K antagonists
(8) Treatment and secondary prophylaxis of venous throm-
boembolism with the new direct oral anticoagulants
(9) Efﬁcacy and safety of reperfusion treatment for patients
at intermediate risk
(10) Early discharge and home (outpatient) treatment of
pulmonary embolism
(11) Current diagnosis and treatment of chronic thromboem-
bolic pulmonary hypertension
(12) Formal recommendations for the management of pulmo-
nary embolism in pregnancy and of pulmonary embolism
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knowledge in respect of optimal diagnosis, assessment and
treatment of patients with PE. This version is update of
previous guidelines published in 2008 [2]. Czech Society of
Cardiology prepared shortened version of the new guidelines,
which is published in this issue of Cor et Vasa [3]. Therefore, in
our article we focussed only on the most clinically relevant
new aspects of 2014-updated version as compared with its
previous version published in 2008.
This update is the most comprehensive set of guidelines yet
in the ﬁeld of acute pulmonary embolism (PE). They include 48
pages with 474 references, more than a dozen tables, and
about half-dozen ﬁgures, plus an appendix of extra tables,
available on the website.
The most clinically relevant new aspects in current version
relate to following issues:
(1) Recently identiﬁed predisposing factors for venous
thromboembolism
(2) Simpliﬁcation of clinical prediction rules
(3) Age-adjusted D-dimer cut-offs
(4) Sub-segmental pulmonary embolism
(5) Incidental, clinically unsuspected pulmonary embolismin patients with cancer.
These new aspects have been integrated into previous
knowledge to suggest optimal and whenever possible objec-
tively validated management strategies for patients with
suspected or conﬁrmed pulmonary embolism. In this article
we stressed main differences present between 2008 and 2014
ESC Guidelines.
Risk factors for VTE
Among predisposing factors for VTE with high risk (odds ratio
>10) are several new factors: hospitalization for heart failure or
atrial ﬁbrillation (within previous 3 months), myocardial
infarction (within previous 3 months) and previous venous
thromboembolism. New moderate risk factors (odds ratio 2–9)
are auto-immune diseases, blood transfusion, erythropoiesis-
stimulating agents, in vitro fertilization, infections (speciﬁcally
pneumonia, urinary tract infection, and HIV), inﬂammatory
bowel disease and superﬁcial vein thrombosis. Finally, new
weak risk factors (odds ratio <2) are diabetes mellitus and
hypertension.
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Clinical presentation
PE may escape prompt diagnosis since clinical signs and
symptoms are non-speciﬁc.
The authors of the ESC Guidelines 2014 stress the non-
speciﬁcity of the following symptoms: dyspnoea, pleuritic chest
pain, cough, substernal chest pain, fever, haemoptysis, syncope,
and signs of DVT (unilateral leg pain). From these only pleuritic
chest pain, haemoptysis, and signs of DVT (unilateral leg pain)
are somewhat more frequent in patients with PE.
According to the both guidelines (2008 and 2014) suspected
acute PE may be divided into two groups: (a) with shock or
hypotension – high risk group and (b) without shock or
hypotension – non-high risk group. Later in the text of new
guidelines you may ﬁnd classiﬁcation into four groups, based
on early mortality risk – (a) high risk, (b) intermediate – high
risk, (c) intermediate – low risk and (d) low risk groups. Risk is
estimated according to presence or absence of the shock or
hypotension, PESI class, signs of RV dysfunction and labora-
tory markers (troponin and BNP).
Assessment of clinical probability
Clinical prediction rules in both texts include Wells and
Geneva score; new guidelines include also simpliﬁed versions
of both Wells and Geneva score (see section ‘‘Diagnosis’’).
D-Dimer testing
The new ESC Guidelines stresses decreasing speciﬁcity of D-
dimer in suspected PE with age to almost 10% in patients >80
years. The new guidelines bring also the diagnostic yield of
various D-dimer assays in excluding acute PE according to
outcome studies, concentrating on the following D-dimer
assays: Vidas Exclusion, SimpliRed and Tinaquant.
Imaging methods
Imaging methods are presented in a changed sequence, new
guidelines starts with description of value of CT pulmonary
angiography, followed by lung scintigraphy, pulmonary
angiography, magnetic resonance angiography, echocardiog-
raphy and compression venous ultrasonography.
Multi-detector CT pulmonary angiography is currently
method of choice for imaging pulmonary vasculature in
patients with suspected PE, as well as lung scintigraphy
remains established diagnostic test, preferentially used in
patients with lower probability, normal chest X-ray, in young
patients, in pregnancy, in patients with strong allergic history,
previous contrast-induced anaphylaxis, severe renal failure
and in patients with myeloma and paraproteinemia. Recent
studies suggest that data acquisition in the tomographic mode
in single photon emission computed tomography (SPECT)
imaging, with or without low-dose CT may reduce the
frequency of non-diagnostic scans. SPECT imaging may even
allow the use of automated detection algorithms for PE.
According to the authors of the new guidelines large-scaleprospective studies are needed to validate these new
approaches.
‘‘Classic’’ pulmonary angiography is currently used only in
patients with catheter directed treatment of acute PE.
Magnetic resonance angiography is now tested for safe
ruling-out of clinically signiﬁcant PE (in combination with
absence of DVT on CUS).
Position of echocardiography in PE diagnosis and the risk
classiﬁcation of PE remain stable and in situations, when CT
angiography is not immediately available, echocardiography
should be used without hesitation. Acute PE may lead to RV
pressure overload and dysfunction, which are detected by
echocardiography, even though echocardiographic criteria for
the diagnosis have differed between studies. New echocardio-
graphic parameters of RV function derived from Doppler tissue
imaging and wall stress assessment were reported to be
affected by the presence of acute PE, but they are not speciﬁc
and may be normal in PE patients haemodynamically stable
(citace 178–181). Lower limb CUS showing a proximal DVT in a
patient with clinical suspicion of PE conﬁrms PE. If CUS shows
only a distal DVT, further testing should be considered to
conﬁrm PE.
Biomarkers
In the new guidelines, biomarkers are referred on in the
section dealing with prognostic assessment of patients with PE
in the section ‘‘Thrombolytic treatment’’, but their values are
not needed for PE diagnosis itself. These markers are basically
same as in the old guidelines, though they are divided into
markers of RV dysfunction, markers of myocardial injury and
non-cardiac markers. Quite new is Table 8 on page 18, where
authors present prediction of early mortality in acute PE using
imaging and laboratory tests based on data from the results of
meta-analyses or when not available thereof, of the largest
prospective cohort studies [2].
Recommendation for prognostic assessment
Simpliﬁed version of PESI – sPESI consists of the following
parameters: age 1 point (if age is >80 years), cancer 1 point,
chronic heart failure or chronic pulmonary disease 1 point,
pulse rate ≥110 b.p.m. 1 point, systolic blood pressure
<100 mmHg 1 point, and arterial oxyhaemoglobin saturation
<90% 1 point.
Treatment
Treatment of acute PE depends on estimated early mortality
risk (see earlier) and in new guidelines has different sections
then before:
Haemodynamic and circulatory support
Haemodynamic and circulatory support with new evidence
from experiments and case reports, which suggest that
extracorporeal cardiorespiratory support can be effective in
massive PE.
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Anticoagulation – ﬁrst parenteral (enoxaparin, tinzaparin,
dalteparin, nadroparin and fondaparinux), second vitamin K
antagonists and third new oral anticoagulants (NOACs)
(dabigatran, rivaroxaban, apixaban and edoxaban). Detailed
summary of new anticoagulation possibilities is provided in
Table 11 page 22 in original article of guidelines. Currently the
use of NOACs in the treatment of VTE is indicated, because
these agents are non-inferior (in terms of efﬁcacy) and possibly
safer (particularly in terms of major bleeding) than the
standard heparin/vitamin K antagonists regiment. Therefore,
the NOACS can be viewed as an alternative to standard
treatment.
Thrombolytic treatment
Thrombolytic treatment – in high risk PE (massive pulmonary
embolism) approved thrombolytic regimens for PE currently
include rtPA, urokinase and streptokinase in accelerated
regime. It must be mentioned: (a) the regime of the half dose
of rtPA is not included in the treatment strategies (10 mg rtPA
as a bolus, and then 40 mg in an 2 h infusion) in spite that in
the older subjects (over 75 years) it decreases the number of
bleeding complications, (b) urokinase is now not available in
the Czech Republic, and (c) streptokinase and urokinase must
be used only the accelerated regimen because the number of
bleeding complications depends on the duration of thrombo-
lytic treatment – the longer duration means the more frequent
bleeding complications. The present recommendation of 2014
ESC Guidelines in patients with intermediate high risk group is
to start all patients on anticoagulation treatment and use
thrombolytic treatment only in patients who are haemody-
namically deteriorating.
Surgical embolectomy
Surgical embolectomy – remains same as before.
Percutaneous catheter-directed treatment
Percutaneous catheter-directed treatment – current interven-
tional options are clearly deﬁned as thrombus fragmentation
systems, rheolytic thrombectomy method, suction thrombec-
tomy and rotational thrombectomy. Results of 35 non-
randomized studies are presented and are very favourable,
with 87% of patients who survived to discharge from the
hospital.
Venous ﬁlters
Venous ﬁlters – in previous version of guidelines mentioned in
other part, here it concludes that currently there are no data to
support the routine use of venous ﬁlters in patients with free-
ﬂoating thrombus in the proximal veins.
Early discharge and home treatment
Early discharge and home treatment – the crucial issue is to
select patients, who are at low risk of an adverse early outcomeThe sPESI seems to be the most extensively validated score to
date. It possesses a high sensitivity for the identiﬁcation of
low-risk PE, but its value for selecting candidates for early
discharge has not yet been directly investigated.
The HESTIA criteria comprise a set of clinical parameters
that can easily be obtained at the bed-side, however they have
not yet been externally validated. In a meta-analysis of 14
(mostly cohort) studies, the pooled incidence of recurrent VTE,
major bleeding and total mortality did not differ signiﬁcantly
between outpatients, patients discharged early and those
treated as inpatients.
Therapeutic strategies
Therapeutic strategies – summary of treatment in PE with
shock or hypotension, without shock or hypotension, similar
as it was in previous guidelines with clear algorithms for acute
treatment presented in the new version – page 27–29.
Chronic thromboembolic pulmonary hypertension
(CTEPH)
Chronic thromboembolic pulmonary hypertension section is
described in much more detailed version in the new guide-
lines. CTEPH has been reported to be a long-term complication
of PE, with a reported cumulative incidence of 0.1–9.1% within
the ﬁrst two years after a symptomatic PE event. Thus routine
screening for CTEPH after PE is not supported by current
evidence; a signiﬁcant number of CTEPH cases develop in the
absence of previous acute PE. Apart from major pulmonary
vascular obstruction, the pathophysiology of CTEPH includes a
pulmonary microvascular disease, which may be responsible
for the poor outcome in some cases of pulmonary endarterec-
tomy. Clinical symptoms and signs are non-speciﬁc or absent
in early CTEPH, with signs of right heart failure only becoming
evident in advanced disease, with a median time of 14 months
between onset of symptoms and diagnosis in expert centres.
The diagnosis of CTEPH is based on ﬁndings obtained after at
least 3 months of effective anticoagulation. While MDCT
angiography is the investigation of choice for the diagnosis of
acute PE, planar V/Q lung scan remains the main ﬁrst-line
imaging modality for CTEPH, as it carries a 96–97% sensitivity
and 90–95% speciﬁcity for the diagnosis. Pulmonary endarter-
ectomy is the treatment of choice for the disease. In Europe, in-
hospital mortality is currently as low as 4.7% in expert centres.
The majority of patients experience substantial relief from
symptoms and near-normalization of haemodynamics. In
contrast to surgical embolectomy for acute pulmonary PE,
treatment of CTEPH necessitates a true endarterectomy
through the medial layer of the pulmonary arteries, which
is performed under deep hypothermia and circulatory arrest.
Patients who do not undergo surgery, or suffer from persistent
or residual pulmonary hypertension after PEA, face a poor
prognosis.
Optimal medical treatment for CTEP consists of life-long
anticoagulation, diuretics, and oxygen. Pulmonary microvas-
cular disease in CTEPH has provided a rationale for use of
drugs approved for pulmonary arterial hypertension. These
drugs may be justiﬁed (a) in inoperable patients and (b) in
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after PEA, or in the presence of an unacceptable surgical risk–
beneﬁt ratio.
Riociguat has received approval for use in symptomatic
patients, who have been classiﬁed as having inoperable CTEPH
by a CTEPH team including at least one experienced surgeon,
or have persistent/recurrent CTEPH after surgical treatment.
Pulmonary embolism in pregnancy
Suspicion of PE in pregnancy warrants formal diagnostic
assessment with validated methods. D-Dimer measurement
may be performed in order to avoid unnecessary irradiation, as
a negative result has a similar signiﬁcance as in non-pregnant
patients.
Venous compression ultrasonography may be considered
in order to avoid unnecessary irradiation, as a diagnosis of
proximal DVT conﬁrms PE. Perfusion scintigraphy may be
considered to rule out suspected PE in pregnant women with
normal chest X-ray. CT angiography should be considered if
the chest X-ray is abnormal or if lung scintigraphy is not
readily available. A weight-adjusted dose of LMWH is the
recommended therapy during pregnancy in patients without
shock or hypotension. New oral anticoagulants are not
indicated in pregnancy.
Pulmonary embolism and cancer
The overall risk of VTE in cancer patients is four times greater
than in the general population, in patients receiving chemo-
therapy is the risk even six times higher and 90-fold in the ﬁrst
week after cancer surgery. Malignancy is taken into account in
the estimation of clinical probability of PE and is a risk factor
for an adverse outcome in acute PE. The worse outcome is due
to the increase risk of bleeding during anticoagulation therapy
and to the high rate of reoccurrence of VTE. Management of PE
in patients with cancer is described in details in the new
guidelines. Important is the new information dealing withpatients who present with unprovoked PE in whom about 10%
will develop cancer within 5–10 years (majority in the ﬁrst 1–2
years) after diagnosis of acute PE. The search for occult cancer
after episode of VTE can be restricted to careful history,
physical examination, laboratory tests and a chest X-ray.
Conﬂict of interest
No conﬂict of interest.
Ethical statement
No ethical issues involved.
Funding body
None.
r e f e r e n c e s
[1] S. Konstantinides, A. Torbicki, G. Agnelli, et al., for the Task
Force for the Diagnosis and Management of Acute
Pulmonary Embolism of the European Society of Cardiology
(ESC), Endorsed by the European Respiratory Society (ERS).
2014 Guidelines on the diagnosis and management of acute
pulmonary embolism, European Heart Journal (2014), http://
dx.doi.org/10.1093/eurheartj/ehu283 (ﬁrst published online
29.08.14).
[2] A. Torbicki, A. Perrier, S. Konstantinides, et al., for the Task
Force for the Diagnosis and Management of Acute
Pulmonary Embolism of the European Society of Cardiology
(ESC), 2008 Guidelines on the diagnosis and management of
acute pulmonary embolism, European Heart Journal 29
(2008) 2276–2315.
[3] R. Rokyta, M. Hutyra, P. Jansa, 2014 ESC Guidelines on the
diagnosis and management of acute pulmonary embolism.
Summary document prepared by the Czech Society of
Cardiology, Cor et Vasa 5 (2015).
